340B Drug Pricing Program
On Feb. 2, a bipartisan group of six senators released a draft bill called the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act.
The AHA 340B Alliance Feb. 22 at 3 p.m. ET will host a call for AHA members about a discussion draft of legislation to provide 鈥渃larity, transparency and accountability to the 340B program.鈥
Register for Feb. 22 AHA call on Senate 340B draft legislation.
Hospitals enrolled in the 340B Drug Pricing program deliver critical services to historically disadvantaged
communities. Their partnerships with community and specialty pharmacies are crucial to providing high-quality,
affordable care and medicine to populations that increasingly face barriers to鈥
A new study published in the New England Journal of Medicine demonstrates a stunning lack of understanding of the 340B drug pricing program and the overall landscape of drug pricing.
A bipartisan group of senators Feb. 2 released for stakeholder feedback a discussion draft of legislation to clarify in statute Congress鈥 intent for the 340B program to help safety net providers maintain, improve and expand patient access to health care services by requiring drug manufacturers that鈥
AHA Dec. 22 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.
UNITED STATES DISTRICT COURT WESTERN DISTRICT OF LOUISIANA LAFAYETTE DIVISION
AHA Dec. 22 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.
Following last year鈥檚 unanimous Supreme Court decision in favor of the AHA and others, the Department of Health and Human Services Nov. 2 issued a final rule outlining the agency鈥檚 remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program.